From its origins in the UK over 20 years ago, Alliance has grown to become a significant international healthcare group, marketing around 80 products in over 100 countries world-wide and employing around 250 people.
Recent years have seen an increasing focus on consumer healthcare products, in addition to the established niche prescription medicines which formed the original focus of the company’s activities. Our products cover a wide range of therapy areas.
In addition to its UK presence, the Group has seven overseas affiliate offices across Europe, the Far East and the US. This geographic presence is enhanced by a broad network of international distributors, covering more than 100 countries worldwide.
Over the years, the business has expanded its UK head office in Chippenham, Wiltshire, and is now one of the main employers in the area.
In March 2022, we acquired both “ScarAway®”, the largest silicone-based scar treatment brand in the US, and the rights to sell Kelo-cote in the retail consumer market in the US, for a consideration of US$19.4m (£14.8m). This acquisition accelerates our strategy in the US, providing another strong consumer brand with an established distribution platform from which to drive further growth, whilst also enabling Kelo-cote to become the Group’s first fully global brand.